Medicament for treating pulmonary infectious diseases and application thereof

A technology for pulmonary infection and disease, applied to the drug for the treatment of pulmonary infectious diseases and its application field, which can solve the problems of unclear medicinal substances and pharmacological effects

Active Publication Date: 2013-12-25
ZHEJIANG ACAD OF MEDICAL SCI
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its medicinal substances and pharmacological effects are still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for treating pulmonary infectious diseases and application thereof
  • Medicament for treating pulmonary infectious diseases and application thereof
  • Medicament for treating pulmonary infectious diseases and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1: Total flavonoids of Artemisia Sifang or Campanulaceae, neohesperidin dihydrochalcone, naringin dihydrochalcone, 7-methoxywogonin, 6,7-dimethoxybaicalein Primer preparation

[0015] 1) After crushing 5Kg Artemisia sifang or Campanula rhizome, add water 10 times the mass of the medicinal material to extract, concentrate to liquid extract (water content about 12%), add 95% ethanol alcohol 5 times the volume of the extract while it is hot Shen;

[0016] 2) Concentrate the ethanol extract under reduced pressure to a liquid extract (with a water content of about 12%), add distilled water 3 times the volume of the extract to suspend, extract with ethyl acetate 4-5 times, each time the amount is a suspension 3 times the volume of ethyl acetate, decompression or vacuum drying to concentrate the ethyl acetate extract to a dry extract, to obtain the total flavonoids of Artemisia sifanglei or Campanula chinensis;

[0017] 3) Take 20g of total flavonoids of Artemisia qu...

Embodiment 2

[0019] Embodiment 2: Drug efficacy test

[0020] 1 Materials and methods

[0021] Ribavirin effervescent tablets (batch number: 091210), Zhejiang Aikang Lide Pharmaceutical Co., Ltd.

[0022] Influenza A virus mouse lung-adapted strain A / PR / 8 / 34, the virus titer is 1:512. This experiment was carried out in the ABSL2 biosafety laboratory of Zhejiang Academy of Medical Sciences.

[0023] 1.1 Animals and grouping

[0024] Clean-grade ICR mice, half male and half female, 18-22 g, provided by Zhejiang Experimental Animal Center, experimental animal license number: SCXK (Zhejiang) 2008-0033. According to body weight, they were randomly divided into 6 groups: normal control group, model control group, ribavirin administration group, neohesperidin dihydrochalcone (NHDC) administration group, naringin dihydrochalcone (NDC) administration group, and naringin dihydrochalcone (NDC) administration group. ) administration group, and the total flavonoids (TF) administration group extract...

Embodiment 3

[0060] Embodiment 3: Drug efficacy test

[0061] 1 Experimental materials

[0062] Clean-grade ICR mice, half male and half female, 18-22 g, provided by Zhejiang Experimental Animal Center, experimental animal license number: SCXK (Zhejiang) 2008-0033.

[0063] Dexamethasone tablets (batch number: 070941), Zhejiang Xianju Pharmaceutical Co., Ltd.; lipopolysaccharide (LPS, batch number: L2880-50MG), American sigma company.

[0064] 2 Experimental methods

[0065] 2.1 Model establishment and grouping

[0066] After adapting to the environment, the mice were randomly divided into 6 groups: normal control group, model group, dexamethasone treatment group, normal control group, model control group, ribavirin administration group and neohesperidin dihydrochalcone (NHDC) administration group, naringin dihydrochalcone (NDC) administration group, total flavonoids (TF) administration group; 10 mice in each group. Continuous intraperitoneal injection for 3 days, 1 time / day, 0.5 hours...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicament for treating pulmonary infectious diseases and an application thereof, which belong to the technical field of medicaments. The medicament comprises any substance or a composition of more than two substances of total flavonoids extracted from elsholtzia blanda or calamint, neohesperidin dihydrochalcone, naringin dihydrochalcone, 7-methoxy wogonin, 6,7-dimethoxy wogonin or pharmaceutically acceptable salts thereof. The invention provides the medicament for treating the pulmonary infectious diseases on one hand, the medicament has such pharmacologic actions as anti-virus, inhibition of virus induced lung injury, pulmonary edema and pneumonia, and reduction of bronchial mucus secretion and the like, and on the other hand, the invention determines the application of the medicament in treating the pulmonary infectious diseases; the medicament can be used for treating acute pneumonia, viral pneumonia, pulmonary edema or bronchitis.

Description

technical field [0001] The invention belongs to the technical field of medicines, in particular to a medicine for treating pulmonary infectious diseases and its application. Background technique [0002] Lung infection accounts for a large proportion of respiratory diseases or infectious diseases. Due to the limitations of current medical conditions, the chances of iatrogenic and secondary pulmonary infections are becoming more and more serious. Although the application of antibiotics and other antimicrobial drugs has effectively controlled the development of the disease in recent years, with the acceleration of genetic mutation of pathogenic microorganisms and the emergence of drug-resistant bacteria (such as superbugs), as well as the reduction of drug sensitivity of patients, lung The overall morbidity and mortality of internal infection have not been significantly reduced, and the long-term use of antibiotics has more obvious toxic and side effects. Natural medicine ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/53A61P11/00A61P31/12A61K31/7034A61K31/7048A61K31/352
Inventor 余陈欢应华忠陈勤钟宇森臧家娜方杰
Owner ZHEJIANG ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap